Table 2.
Marginal Risk of Clinical Outcomes by eGFR Slope.
| Outcome | eGFR decrease, mL/min/1.73 m2/year | |||||
|---|---|---|---|---|---|---|
| 0 | 1 | 2 | 5 | 10 | 15 | |
| ESKD | 0.2 (0.2, 0.2) | 0.2 (0.2, 0.2) | 0.2 (0.2, 0.3) | 0.3 (0.3, 0.3) | 0.4 (0.4, 0.4) | 0.5 (0.4, 0.6) |
| New MI | 0.4 (0.4, 0.4) | 0.4 (0.4, 0.4) | 0.4 (0.4, 0.4) | 0.4 (0.3, 0.5) | 0.4 (0.3, 0.6) | 0.5 (0.2, 0.7) |
| New stroke | 1.1 (1.0, 1.1) | 1.1 (1.0, 1.1) | 1.1 (1.1, 1.2) | 1.2 (1.1, 1.3) | 1.4 (1.2, 1.6) | 1.6 (1.2, 2.0) |
| Heart failure | 1.2 (1.2, 1.3) | 1.3 (1.3, 1.3) | 1.4 (1.4, 1.4) | 1.7 (1.6, 1.9) | 2.5 (2.2, 2.8) | 3.6 (2.9, 4.3) |
| Hospitalization | ||||||
| All-cause | 12.3 (12.2, 12.4) | 12.8 (12.7, 12.9) | 13.3 (13.2, 13.5) | 15.0 (14.7, 15.3) | 18.2 (17.5, 19.0) | 21.9 (20.6, 23.2) |
| Kidney | 1.0 (0.9, 1.0) | 1.0 (1.0, 1.0) | 1.0 (1.0, 1.1) | 1.2 (1.1, 1.3) | 1.5 (1.3, 1.7) | 1.9 (1.5, 2.3) |
| Cardiovascular | 2.1 (2.0, 2.1) | 2.1 (2.1, 2.2) | 2.2 (2.2, 2.3) | 2.5 (2.4, 2.6) | 3.0 (2.7, 3.3) | 3.6 (3.1, 4.1) |
| MI | 0.4 (0.4, 0.5) | 0.4 (0.4, 0.5) | 0.4 (0.4, 0.5) | 0.4 (0.4, 0.5) | 0.5 (0.3, 0.6) | 0.5 (0.3, 0.7) |
| Stroke | 0.3 (0.3, 0.3) | 0.3 (0.3, 0.3) | 0.3 (0.3, 0.4) | 0.4 (0.3, 0.4) | 0.4 (0.3, 0.6) | 0.5 (0.3, 0.7) |
| Heart failure | 0.4 (0.4, 0.5) | 0.5 (0.4, 0.5) | 0.5 (0.5, 0.5) | 0.6 (0.5, 0.6) | 0.7 (0.6, 0.8) | 0.9 (0.7, 1.1) |
| Mortality | ||||||
| All-cause | 2.1 (2.1, 2.2) | 2.3 (2.2, 2.3) | 2.5 (2.4, 2.5) | 3.1 (3.0, 3.2) | 4.4 (4.1, 4.8) | 6.3 (5.6, 7.0) |
| Kidney | 0.1 (0.0, 0.1) | 0.1 (0.0, 0.1) | 0.1 (0.0, 0.1) | 0.1 (0.1, 0.1) | 0.1 (0.1, 0.1) | 0.1 (0.0, 0.2) |
| Cardiovascular | 0.7 (0.6, 0.7) | 0.7 (0.7, 0.7) | 0.7 (0.7, 0.8) | 0.9 (0.8, 1.0) | 1.2 (1.0, 1.4) | 1.6 (1.3, 2.0) |
Note. ACE = angiotensin-converting enzyme; ARB = angiotensin II receptor blockers; eGFR = estimated glomerular filtration rate; ESKD = end-stage kidney disease; HbA1c = glycated hemoglobin; MI = myocardial infarction; SGLT2 = sodium-glucose cotransporter-2; TIA = transient ischemic attack.
Risk (%) with 95% confidence intervals are presented for Model 2 which parametrizes eGFR slopes that were negative with a linear term and an indicator for missing slope. Positive slopes were assigned a slope value of 0. The model also adjusted for baseline eGFR (≥90, 60-<90, 45-<60, 30-<45, 15-<30, <15 mL/min/1.73 m2, and missing), albuminuria (none/mild, moderate, severe, missing), glycated hemoglobin (<7%, 7-8%, >8-9%, >9%, and missing), age, biological sex, rural status, comorbidities (atrial fibrillation, heart failure, coronary artery disease, peripheral artery disease, stroke, and retinopathy) and prescriptions filled (SGLT2 inhibitors, ACE inhibitors, or ARBs, and statins).